U.K. committee releases Orkambi documents; pricing details lacking

As NICE, NHS England and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) remain at an impasse over the pricing of cystic fibrosis drug Orkambi ivacaftor/lumacaftor, a U.K. parliamentary committee made good on its promise on Dec. 20, releasing a slew of documents from the three parties.

After the three parties failed to reach a reimbursement deal by Nov. 30, the House of Commons Health and Social Care Committee released the documents as promised in a Nov. 7 ultimatum. Vertex spokesperson Rob Clark confirmed with BioCentury Dec. 20 that there is still no deal (see "Vertex, NICE, NHS Miss Orkambi Deadline").

The batch of published documents do not

Read the full 1021 word article

User Sign In